Sign in

    Yuxi Dong • Jefferies

    Yuxi Dong's questions to Revolution Medicines Inc (RVMD) leadership

    Yuxi Dong's questions to Revolution Medicines Inc (RVMD) leadership • Q1 2025

    Question

    Yuxi Dong, on behalf of Kelly Shi at Jefferies, inquired about the key criteria for resource allocation across the company's broad pipeline, including NSCLC, pancreatic cancer, and early-stage programs, and asked about the expected cadence for initiating pivotal combination trials in lung cancer.

    Answer

    Dr. Mark Goldsmith, CEO, stated that first-line combination trials are expected to begin rolling out in 2026. Regarding resource allocation, he described it as a complex decision driven by clinical data, biological rationale, the competitive landscape, and the potential to deliver durable clinical benefit. He emphasized that the company's strong financial position allows it to advance all high-priority programs to establish a leading RAS franchise.

    Ask Fintool Equity Research AI

    Yuxi Dong's questions to Revolution Medicines Inc (RVMD) leadership • Q4 2024

    Question

    Yuxi Dong, on behalf of Kelly Shi at Jefferies, asked if the company plans to provide an update on the median overall survival (OS) data for the daraxonrasib Phase I study in PDAC, which was previously immature.

    Answer

    CEO Dr. Mark Goldsmith clarified that a median OS estimate of 14.5 months was previously reported for an aggregate of dose cohorts. The specific 300mg cohort was less mature. He confirmed the data continues to mature and an update will likely be provided at some point, but there is no specific timeline for the disclosure.

    Ask Fintool Equity Research AI

    Yuxi Dong's questions to Ocular Therapeutix Inc (OCUL) leadership

    Yuxi Dong's questions to Ocular Therapeutix Inc (OCUL) leadership • Q4 2024

    Question

    Yuxi Dong, on for Kelly Shi, asked if the long-term redosing durability data from SOL-1 would be available by the time of the NDA submission, which is planned after the SOL-R primary endpoint is reached. She also sought to clarify if the FDA requires this specific data to support redosing flexibility on the product label.

    Answer

    President and CEO Dr. Pravin Dugel clarified that the NDA submission requires positive primary endpoints from SOL-1 (at 9 months) and SOL-R (at 56 weeks). While the longer-term redosing data is not required for the initial submission, it will fulfill FDA safety requirements and generate a wealth of data, including a numeric comparison to high-dose Eylea, which the company can leverage for a stronger commercial label.

    Ask Fintool Equity Research AI